Literature DB >> 9592391

Intercellular delivery of functional p53 by the herpesvirus protein VP22.

A Phelan1, G Elliott, P O'Hare.   

Abstract

The herpes simplex virus type 1 (HSV-1) virion protein VP22 exhibits the remarkable property of intercellular trafficking whereby the protein spreads from the cell in which it is synthesized to many surrounding cells. In addition to having implications for protein trafficking mechanisms, this function of VP22 might be exploited to overcome a major hurdle in gene therapy, i.e., efficient delivery of genes and gene products. We show that chimeric polypeptides, consisting of VP22 linked to the entire p53 protein, retain their ability to spread between cells and accumulate in recipient cell nuclei. Furthermore the p53-VP22 chimeric protein efficiently induces apoptosis in p53 negative human osteosarcoma cells resulting in a widespread cytotoxic effect. The intercellular delivery of functional p53-VP22 fusion protein is likely to prove beneficial in therapeutic strategies based on restoration of p53 function. These results, demonstrating intracellular transport of large functional proteins, indicate that VP22 delivery may have applications in gene therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592391     DOI: 10.1038/nbt0598-440

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  56 in total

1.  Evaluation of strategies for the intracellular delivery of proteins.

Authors:  Dongjiu Ye; Dong Xu; Alex U Singer; R L Juliano
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Might a vanguard of mRNAs prepare cells for the arrival of herpes simplex virus?

Authors:  Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

3.  The attenuated pseudorabies virus strain Bartha fails to package the tegument proteins Us3 and VP22.

Authors:  Mathew G Lyman; Gretchen L Demmin; Bruce W Banfield
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.

Authors:  Saskia A Rutjes; Piter J Bosma; Jennifer L Rohn; Mathieu H M Noteborn; John G Wesseling
Journal:  J Mol Med (Berl)       Date:  2003-07-16       Impact factor: 4.599

Review 5.  Transducing proteins to manipulate intracellular targets.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2003-08-19       Impact factor: 4.599

Review 6.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

7.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

8.  Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations.

Authors:  J S Harms; X Ren; S C Oliveira; G A Splitter
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 9.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

10.  The varicella-zoster virus (VZV) ORF9 protein interacts with the IE62 major VZV transactivator.

Authors:  Cristian Cilloniz; Wallen Jackson; Charles Grose; Donna Czechowski; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.